Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers.

B A Vesely1, E J Eichelbaum, A A Alli

  • 1James A. Haley Veterans Medical Center and University of South Florida Health Sciences Center, Tampa, 33612, USA.

European Journal of Clinical Investigation
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line.

In vitro cellular & developmental biology. Animal·2015
Same author

Cardiac hormones eliminate some human squamous lung carcinomas in athymic mice.

European journal of clinical investigation·2010
Same author

Cardiac hormones activate ERK 1/2 kinases in human fibroblasts.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2008
Same author

Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice.

European journal of clinical investigation·2008
Same author

Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6 protection against p53-induced apoptosis in M1 myeloid leukemic cells.

Oncogene·2006
Same author

Circadian distribution of hematology variables in subjects with multiple sclerosis.

La Clinica terapeutica·2006
Same journal

Pacemaker Status and 5-Year Mortality After TAVI: A Sex-Specific Analysis.

European journal of clinical investigation·2026
Same journal

Causal Effects of Time-Varying Treatments: The G-Formula.

European journal of clinical investigation·2026
Same journal

Improving Scientific Research: Renegotiated Principles of Science, Proposals, Failures, and Successes.

European journal of clinical investigation·2026
Same journal

Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With Trial Sequential Analysis.

European journal of clinical investigation·2026
Same journal

Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.

European journal of clinical investigation·2026
Same journal

Circulating Human Epididymis Protein 4 Predicts 10-Year Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Artery Disease.

European journal of clinical investigation·2026
See all related articles

Natriuretic peptides, including urodilatin and four cardiac hormones, show potent anti-cancer effects against renal carcinoma cells. These peptide hormones eliminated up to 81% of cancer cells within 24 hours, offering a promising new avenue for cancer treatment.

Area of Science:

  • Cardiovascular Endocrinology
  • Nephrology
  • Oncology

Background:

  • Renal-cell cancer (RCC) poses a significant mortality risk, with limited success from current treatments.
  • Four cardiac natriuretic peptides have demonstrated anti-cancer properties in various adenocarcinomas.

Purpose of the Study:

  • To evaluate the anti-cancer effects of several natriuretic peptides and urodilatin in renal carcinomas.
  • To investigate the presence of natriuretic peptide receptors in renal cancer cells.

Main Methods:

  • Seven peptide hormones (atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, brain natriuretic peptide (BNP), C-natriuretic peptide (CNP), and urodilatin) were tested.
  • Dose-response studies and DNA synthesis assays were performed on human renal carcinoma cells.

Related Experiment Videos

  • Western blotting was used to detect natriuretic peptide receptors (NPRs).

    • Main Results:

    • Vessel dilator, kaliuretic peptide, urodilatin, atrial natriuretic peptide, and long-acting natriuretic peptide significantly reduced renal carcinoma cell count by up to 81% within 24 hours.
    • BNP showed no effect, while CNP had a minimal effect on cell number.
    • These peptide hormones, along with urodilatin, significantly decreased DNA synthesis (65-84%).
    • Natriuretic peptide receptors (NPR-A, -B, and -C) were detected in renal cancer cells.

    Conclusions:

    • Urodilatin and four cardiac hormones exhibit potent anti-cancer activity against renal carcinoma cells.
    • These findings suggest a potential therapeutic role for specific natriuretic peptides in RCC treatment.
    • The presence of NPRs indicates a mechanism for peptide hormone action in renal cancer cells.